The overenrollment in our trial1 resulted from an unanticipated jump in patient randomization at several large research centers, just as we were nearing the 200-patient mark. Using the day we accrued the 200th patient as a cutoff, we have now identified the first 209 randomized patients. Analysis of their data confirmed the superiority of Pennsaid (a topical 1.5% [wt/wt] diclofenac sodium solution in a carrier containing dimethyl sulfoxide [Dimethaid Health Care Ltd, Markham, Ontario]) (pain, P<.001; physical function, P<.001; patient global assessment, P = .002; mean difference between groups for pain, 2.3).
Roth SH, Shainhouse JZ. Efficacy and Relevance of Topical Diclofenac for Osteoarthritic Pain—Reply. Arch Intern Med. 2005;165(5):589-590. doi:10.1001/archinte.165.5.589